{"id":"NCT02076412","sponsor":"Rigel Pharmaceuticals","briefTitle":"A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2016-08","completion":"2016-08","firstPosted":"2014-03-03","resultsPosted":"2019-01-25","lastUpdate":"2019-01-25"},"enrollment":74,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Immune Thrombocytopenic Purpura"],"interventions":[{"type":"DRUG","name":"Fostamatinib Disodium","otherNames":["R935788","R788","Fostamatinib"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fostamatinib Disodium","type":"EXPERIMENTAL"},{"label":"Placebo","type":"OTHER"}],"summary":"The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).","primaryOutcome":{"measure":"Number of Participants With Stable Platelet Response of at Least 50,000/ÂµL","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Fostamatinib Recipient","deltaMin":9,"sd":null},{"arm":"Placebo Recipient","deltaMin":1,"sd":null}],"pValues":[{"comp":"OG000","p":"0.1519"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":35,"countries":["United States","Austria","Bulgaria","Czechia","Germany","Norway","Poland","Romania","Spain"]},"refs":{"pmids":["33995988"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":51},"commonTop":["Diarrhoea","Hypertension","Nausea","Epistaxis","Headache"]}}